Spero Therapeutics Inc.

SPRO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.41

+$0.27 (+23.68%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+23.68%

(1D)

Rating

Updated: Aug 18, 2026

70.5

Fundamentals Excellent

Market Sentiment Bearish

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $81.64M

1D Range

1.28 1.44

52W Range

1.08 3.08

Valuation (TTM)

PE 10.36

PB 1.49

EV/EBITDA 2.24

Valuation (NTM)

Forward PE 1.65

Forward PEG -0.11

Price Target $6

Cash Flow

FCF Yield 29.7%

SBC Adj. FCF Yield 23.6%

SBC Impact -20.4%

Margins

Gross Margin 100.0%

Operating Margin 14.0%

FCF Margin 45.6%

Growth (CAGR)

Revenue 3Y | 5Y -6.3% | 22.9%

Dil EPS 3Y | 5Y -60.0% | 75.8%

FCF 3Y | 5Y 17.8% | 82.0%

Returns

ROA 14.0%

ROE 16.2%

ROIC 12.6%

Financial Health

Net Cash

$50.77M

Current Ratio 6.12

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant ...

Sector Healthcare

Industry Biotechnology

Employees 25

IPO Date Nov 1, 2017

Website sperotherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 16, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+325.53%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞